戻る
Black Diamond Therapeutics Inc (BDTX)価格
BDTX 株価推移チャート
BDTX 財務
Black Diamond Therapeutics Inc
$2.19
-1.35%
$-0.03
終値： Feb 12, 16:00:00 GMT-5
$2.2
0.45%
$0.01
アフターマーケット：Feb 12, 19:08:13 GMT-5
主要データ
前終値
$2.22
始値
$2.22
当日レンジ
$2.13 - $2.24
52週レンジ
$1.19 - $4.94
取引高
431.9K
平均取引高
1.1M
1株当たり利益(TTM)
0.36
配当利回り
--
時価総額
$125.3M
BDTXとは何ですか？
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.